A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally. We were incorporated in 1998 and target an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market as well as other healthcare / medical and consumer goods markets. We are also exploring new opportunities in large medical markets outside of the dermatology market such as obesity and other potential markets where a topical or transdermal solution would be a viable alternative. With the research and development complete on forty products and numerous patents issued (technology and product patents), we are ready to monetize our investment.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 20K | - | - | - | 663K | - |
| Net Income | -491K | -566K | -2.4M | -1.2M | -1.1M | -1.4M |
| EPS | $-0.07 | $-0.11 | $-0.52 | $-0.27 | $-0.24 | $-0.32 |
| Free Cash Flow | 0 | -70K | -77K | 45K | 375K | 46K |
| ROIC | -343.4% | -294.4% | -237.9% | -96.6% | 82.7% | -100.1% |
| Gross Margin | 100.0% | - | - | - | 99.5% | - |
| Debt/Equity | 0.00 | -0.58 | -0.60 | -0.07 | -0.09 | -0.17 |
| Dividends/Share | $0.00 | - | - | - | $0.00 | $0.00 |
| Operating Income | -581K | -590K | -490K | -238K | 188K | -254K |
| Operating Margin | -2904.4% | - | - | - | 28.3% | - |
| ROE | 0.0% | - | - | - | 0.0% | 0.0% |
| Shares Outstanding | 5M | 5M | 5M | 5M | 4M | 5M |
SKINVISIBLE, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 99.5%. At current prices, the estimated annualized return to fair value is +34.3%.
SKINVISIBLE, INC. (SKVI) has a 5-year average return on invested capital (ROIC) of -38.0%. This is below average and may indicate limited pricing power.
SKINVISIBLE, INC. (SKVI) has a market capitalization of $2M. It is classified as a small-cap stock.
SKINVISIBLE, INC. (SKVI) does not currently pay a regular dividend.
SKINVISIBLE, INC. (SKVI) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
SKINVISIBLE, INC. (SKVI) generated $-70 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SKINVISIBLE, INC. (SKVI) reported earnings per share (EPS) of $-0.11 in its most recent fiscal year.
SKINVISIBLE, INC. (SKVI) has a 5-year average gross margin of 99.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for SKINVISIBLE, INC. (SKVI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SKINVISIBLE, INC. (SKVI) has a book value per share of $-1.80, based on its most recent annual SEC filing.
No recent press releases.